OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Oculis Holding AG
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 4, 2026
$7.32+0.03 (+0.41%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 5.96 | |
| Interest coverage | – | -4.7× | -98.0× | |
| Diluted shares | – | 3M | 52M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Oculis generated CHF 209.16M from operations and spent CHF 672.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
CHF 209.16M
Used
CHF 672.00K
Capital expenditureCHF 672.00K100%DividendsCHF 00%Share buybacksCHF 00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-CHF 66.30M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CHF 66.30M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.37 → 5.96
- No dilutionShare count did not rise40M → 52M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –